Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017; 18: 357-370.

Published: 26th April 2017

Authors: Cunningham D, Stenning SP , Smyth EC, Okines AF, Allum WH, Rowley S et al.

Conclusion

In this trial that included 1063 patients, the addition of bevacizumab did not improve 3-year survival: 48.1 per cent compared to 50.3 per cent in the standard chemotherapy group (P=0.36). More patients in the bevacizumab group had an anastomotic leak after oesophagectomy: 24 versus 10 per cent.

Pubmed Link

Your comments

0 Comments